Target type: biologicalprocess
Any process that increases the rate, frequency or extent of cGMP-mediated signaling. [GOC:BHF, GOC:dph, GOC:tb]
Positive regulation of cGMP-mediated signaling is a complex biological process that involves the activation of signaling pathways mediated by cyclic guanosine monophosphate (cGMP). cGMP is a second messenger molecule that plays a crucial role in various cellular processes, including smooth muscle relaxation, neurotransmission, and phototransduction. The process begins with the activation of guanylate cyclase enzymes, which catalyze the conversion of GTP to cGMP. This activation can be triggered by various stimuli, such as hormones, neurotransmitters, or light. Once cGMP is produced, it binds to and activates downstream effector proteins, such as protein kinases and ion channels. These activated effector proteins initiate a cascade of signaling events that ultimately lead to specific cellular responses. For example, in smooth muscle cells, cGMP activation leads to the relaxation of muscle fibers by activating protein kinase G, which phosphorylates and inactivates myosin light chain kinase. This inactivation prevents myosin from binding to actin, resulting in muscle relaxation. In photoreceptor cells, cGMP activation regulates the flow of ions through ion channels, leading to the transduction of light signals. The process of positive regulation of cGMP-mediated signaling involves a delicate balance between the production and degradation of cGMP. Phosphodiesterases (PDEs) are enzymes that catalyze the breakdown of cGMP, terminating the signaling pathway. The activity of PDEs is regulated by various factors, including intracellular calcium levels and phosphorylation. Dysregulation of cGMP signaling can lead to various pathological conditions, including cardiovascular diseases, neurological disorders, and retinal diseases. Therefore, understanding the intricate mechanisms of positive regulation of cGMP-mediated signaling is essential for developing novel therapeutic strategies for these diseases.'
"
Protein | Definition | Taxonomy |
---|---|---|
Adenosine receptor A2b | An adenosine receptor A2b that is encoded in the genome of human. [PRO:WCB, UniProtKB:P29275] | Homo sapiens (human) |
Atrial natriuretic peptide receptor 1 | An atrial natriuretic peptide receptor 1 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P16066] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
9-ethyladenine | |||
1,3-diethyl-8-phenylxanthine | 1,3-diethyl-8-phenylxanthine: structure given in first source | ||
1,3-dipropyl-8-cyclopentylxanthine | DPCPX : An oxopurine that is 7H-xanthine substituted at positions 1 and 3 by propyl groups and at position 8 by a cyclohexyl group. | oxopurine | adenosine A1 receptor antagonist; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor |
1,3-dipropyl-8-(4-sulfophenyl)xanthine | 1,3-dipropyl-8-(4-sulfophenyl)xanthine: adenosine receptor antagonist | ||
enprofylline | enprofylline : Xanthine bearing a propyl substituent at position 3. A bronchodilator, it is used for the symptomatic treatment of asthma and chronic obstructive pulmonary disease, and in the management of cerebrovascular insufficiency, sickle cell disease, and diabetic neuropathy. | oxopurine | anti-arrhythmia drug; anti-asthmatic drug; bronchodilator agent; non-steroidal anti-inflammatory drug |
5-(n,n-hexamethylene)amiloride | 5-(N,N-hexamethylene)amiloride : A member of the class of pyrazines that is amiloride in which the two amino hydrogens at position N-5 are replaced by a hexamethylene moiety, resulting in the formation of an azepane ring. 5-(N,N-hexamethylene)amiloride: inhibitor of Na+-H+ exchange; has anti-HIV-1 activity | aromatic amine; azepanes; guanidines; monocarboxylic acid amide; organochlorine compound; pyrazines | antineoplastic agent; apoptosis inducer; odorant receptor antagonist; sodium channel blocker |
7-(2-chloroethyl)theophylline | 7-(2-chloroethyl)theophylline: adenosine antagonist | oxopurine | |
etofylline | etofylline: etophyllin appeared once in PubMed: Wien Med Wochenschr. 1986 May 15;136(9):213-8 as a combination drug with theophylline (spelt without e, theophllin) | oxopurine | |
8-(4-sulfophenyl)theophylline | 8-(4-sulfophenyl)theophylline: adenosine antagonist | ||
8-cyclopentyl-1,3-dimethylxanthine | 8-cyclopentyl-1,3-dimethylxanthine: prolongs epileptic seizures in rats | oxopurine | |
8-phenyltheophylline | 8-phenyltheophylline: purinergic P1 receptor antagonist | ||
theophylline | dimethylxanthine | adenosine receptor antagonist; anti-asthmatic drug; anti-inflammatory agent; bronchodilator agent; drug metabolite; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; fungal metabolite; human blood serum metabolite; immunomodulator; muscle relaxant; vasodilator agent | |
caffeine | purine alkaloid; trimethylxanthine | adenosine A2A receptor antagonist; adenosine receptor antagonist; adjuvant; central nervous system stimulant; diuretic; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; environmental contaminant; food additive; fungal metabolite; geroprotector; human blood serum metabolite; mouse metabolite; mutagen; plant metabolite; psychotropic drug; ryanodine receptor agonist; xenobiotic | |
cgs 15943 | 9-chloro-2-(2-furyl)-(1,2,4)triazolo(1,5-c)quinazolin-5-imine: non-xanthine triazoloquinazoline adenosine antagonist CGS 15943 : A member of the class of triazoloquinazolines that is [1,2,4]triazolo[1,5-c]quinazoline substited at positions 2, 5 and 9 by furan-2-yl, amino and chloro groups respectively. A potent antagonist at adenosine A1 and adenosine A2A receptors. | aromatic amine; biaryl; furans; organochlorine compound; primary amino compound; quinazolines; triazoloquinazoline | adenosine A1 receptor antagonist; adenosine A2A receptor antagonist; antineoplastic agent; central nervous system stimulant |
denbufylline | denbufylline: structure given in first source | oxopurine | |
1-methyl-3-isobutylxanthine | 1-Methyl-3-isobutylxanthine: A potent cyclic nucleotide phosphodiesterase inhibitor; due to this action, the compound increases cyclic AMP and cyclic GMP in tissue and thereby activates CYCLIC NUCLEOTIDE-REGULATED PROTEIN KINASES 3-isobutyl-1-methylxanthine : An oxopurine that is xanthine which is substituted at positions 1 and 3 by methyl and isobutyl groups, respectively. | 3-isobutyl-1-methylxanthine | |
ns 2028 | NS 2028: structure in first source | ||
pentoxifylline | oxopurine | ||
8-(4-((2-aminoethyl)aminocarbonylmethyloxy)phenyl)-1,3-dipropylxanthine | 8-(4-((2-aminoethyl)aminocarbonylmethyloxy)phenyl)-1,3-dipropylxanthine: adenosine receptor antagonist | ||
6-phenyl-1,3,5-triazine-2,4-diamine | 6-phenyl-1,3,5-triazine-2,4-diamine: structure in first source | ||
2-chloroadenosine | 5-chloroformycin A: structure given in first source | purine nucleoside | |
9-benzyladenine | |||
adenosine | quinquefolan B: isolated from roots of Panax quinquefolium L.; RN not in Chemline 10/87; RN from Toxlit | adenosines; purines D-ribonucleoside | analgesic; anti-arrhythmia drug; fundamental metabolite; human metabolite; vasodilator agent |
rolofylline | rolofylline: selective antagonist for adenosine receptors; a cardiovascular agent | oxopurine | |
isoguanosine | purine nucleoside | ||
aristeromycin | aristeromycin: RN given refers to (1R-(1alpha,2alpha,3beta,5alpha)-isomer | ||
metrifudil | |||
acefylline | acefylline: RN given refers to parent cpd | oxopurine | |
9-methyladenine | 9-methyladenine : Adenine substituted with a methyl group at position N-9. | methyladenine | metabolite |
3-methylxanthine | 3-methyl-7H-xanthine : A 3-methylxanthine tautomer where the imidazole proton is located at the 7-position. 3-methyl-9H-xanthine : A 3-methylxanthine tautomer where the imidazole proton is located at the 9-position. | 3-methylxanthine | metabolite |
7-methyladenine | 7-methyladenine : Adenine substituted with a methyl group at position N-7. 7-methyladenine: potential marker for monitoring exposure to methylatingcarcinogens | methyladenine | metabolite |
9-(2,3-dihydroxypropyl)adenine, (s)-isomer | |||
1-methylxanthine | 1-methyl-7H-xanthine : A 1-methylxanthine tautomer where the imidazole proton is located at the 7-position. 1-methylxanthine : A monomethylxanthine having the methyl group located at the 1-position. It is a metabolite of caffeine in humans. 1-methylxanthine: urinary metabolite of caffeine | 1-methylxanthine | mouse metabolite |
8-bromoadenine | 8-bromoadenine: affects DNA repair | ||
n(6)-benzyladenosine | N(6)-benzyladenosine: RN given refers to parent cpd | ||
phenylisopropyladenosine | aromatic amine; benzenes; hydrocarbyladenosine; purine nucleoside; secondary amino compound | adenosine A1 receptor agonist; neuroprotective agent | |
5'-n-methylcarboxamideadenosine | 5'-N-methylcarboxamideadenosine: RN given refers to (beta-D)-isomer | ||
3,7-dimethyl-1-propargylxanthine | 3,7-dimethyl-1-propargylxanthine: potent & selective in vivo antagonist of adenosine analogs | ||
n(6)-phenyladenosine | purine nucleoside | ||
n-methyladenosine | N-methyladenosine: is a inhibitor of cell differentiation N(6)-methyladenosine : A methyladenosine compound with one methyl group attached to N(6) of the adenine nucleobase. | methyladenosine | |
bw a1433u | BW A1433U: adenosine A3 receptor antagonist; attenuates hypoxia-induced AH interval prolongation; derivative of 1,3-dipropyl-8-phenylxanthine | ||
n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine | 3-iodobenzyl-5'-N-methylcarboxamidoadenosine : A derivative of adenosine in which the 5'-hydroxymethyl group is replaced by N-ethylcarboxamido and one of the hydrogens of the exocyclic amino function is substituted by a 3-iodobenzyl group. N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine: structure given in first source; a selective A(3) adenosine receptor agonist | adenosines; monocarboxylic acid amide; organoiodine compound | adenosine A3 receptor agonist |
2-chloro-n(6)cyclopentyladenosine | 2-chloro-N(6)cyclopentyladenosine: highly selective agonist at A1 adenosine receptors | ||
8-(4-carboxymethyloxy)phenyl-1,3-dipropylxanthine | 8-(4-carboxymethyloxy)phenyl-1,3-dipropylxanthine: used to localize adenosine receptors in the brain | ||
1-propylxanthine | 1-propylxanthine: structure given in first source | ||
salvinorin a | salvinorin A: from the herb, Salvia divinorum | organic heterotricyclic compound; organooxygen compound | metabolite; oneirogen |
1,3-dipropyl-8-phenylxanthine | 1,3-dipropyl-8-phenylxanthine: selective antagonist at adenosine A1 receptors | oxopurine | |
8-(dicyclopropylmethyl)-1,3-dipropylxanthine | 8-(dicyclopropylmethyl)-1,3-dipropylxanthine: selective A1 adenosine receptor antagonist; structure given in first source | ||
kfm 19 | KFM 19: a potential cognitive enhancer and a selective adenosine A1 receptor antagonist | ||
2-(1-octynyl)adenosine | YT 146: an adenosine receptor agonist; structure given in first source | ||
1-isoamyl-3-isobutylxanthine | |||
tecadenoson | tecadenoson: an A1 adenosine receptor agonist | ||
1-deazaadenosine | 1-deazaadenosine: inhibits nucleic acid & protein synthesis; structure given in first source | ||
1,3-dipropyl-7-methylxanthine | 1,3-dipropyl-7-methylxanthine: structure given in first source | ||
bw a522 | BW A522: blocks adenosine A3 receptor-mediated hypotensive responses in rats | ||
2-hexynyladenosine-5'-n-ethylcarboxamide | 2-hexynyladenosine-5'-N-ethylcarboxamide: adenosine receptor agonist | ||
1,3-dipropylxanthine | 1,3-dipropylxanthine: has high affinity for adenosine receptors; structure given in first source | ||
zm 241385 | ZM 241385: a high affinity radioligand selective for the A2a adenosine receptor | diamino-1,3,5-triazine | |
sch 58261 | triazolopyrimidines | ||
l 734005 | 5-chloro-3-phenylthioindole-2-carboxamide: structure given in first source; an inhibitor of HIV-1 reverse transcriptase | ||
regadenoson | purine nucleoside | ||
8-cyclohexylcaffeine | |||
5'-methylthioadenosine | 5'-methylthioadenosine: structure 5'-S-methyl-5'-thioadenosine : Adenosine with the hydroxy group at C-5' substituted with a methylthio (methylsulfanyl) group. | thioadenosine | algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite |
adenosine-5'-(n-ethylcarboxamide) | Adenosine-5'-(N-ethylcarboxamide): A stable adenosine A1 and A2 receptor agonist. Experimentally, it inhibits cAMP and cGMP phosphodiesterase activity. N-ethyl-5'-carboxamidoadenosine : A derivative of adenosine in which the 5'-hydroxymethyl group is replaced by an N-ethylcarboxamido group. | adenosines; monocarboxylic acid amide | adenosine A1 receptor agonist; adenosine A2A receptor agonist; antineoplastic agent; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; vasodilator agent |
roflumilast | aromatic ether; benzamides; chloropyridine; cyclopropanes; organofluorine compound | anti-asthmatic drug; phosphodiesterase IV inhibitor | |
wr-142,490 | (+)-(11R,2'S)-erythro-mefloquine : An optically active form of [2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanol having (+)-(11R,2'S)-erythro-configuration. An antimalarial agent, used in racemic form, which acts as a blood schizonticide; its mechanism of action is unknown. | [2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanol | antimalarial |
1-deaza-2-chloro-n(6)-cyclopentyladenosine | 1-deaza-2-chloro-N(6)-cyclopentyladenosine: adenosine A(1) receptor agonist | ||
n(6)-cyclopentyladenosine | |||
4-(2-furanyl)-6-methyl-2-sulfanylidene-3,4-dihydro-1H-pyrimidine-5-carboxylic acid ethyl ester | pyrimidinecarboxylic acid | ||
2-chloro-n(6)-(3-iodobenzyl)adenosine-5'-n-methyluronamide | 2-chloro-N(6)-(3-iodobenzyl)adenosine-5'-N-methyluronamide: structure given in first source | ||
adenosine-5'-(N-propyl)carboxamide | adenosine-5'-(N-propyl)carboxamide : A monocarboxylic acid amide that is the propyl amide of adenosine 5'-carboxylic acid. | adenosines; monocarboxylic acid amide | |
2-(4-(2-carboxyethyl)phenethylamino)-5'-n-ethylcarboxamidoadenosine | 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine: A2 adenosine receptor agonist; structure given in first source CGS-21680 : A derivative of adenosine in which the 5'-hydroxymethyl group is replaced by N-ethylcarboxamido and the hydrogen at position 2 on the adenine is replaced by a 4-(2-carboxyethyl)phenethylamino group. | adenosines; dicarboxylic acid monoamide; monocarboxylic acid | adenosine A2A receptor agonist; anti-inflammatory agent |
mrs 1523 | 2,3-diethyl-4,5-dipropyl-6-phenylpyridine-3-thiocarboxylate-5-carboxylate: adenosine A3 receptor antagonist | ||
mre 3008-f20 | MRE 3008-F20: InChIKey: CJRNHKSLHHWUAB-UHFFFAOYSA-N | ||
istradefylline | oxopurine | ||
osip 339391 | UCS15A: from Streptomyces; structure in first source | ||
psb 1115 | oxopurine | ||
n-(1-methyl-2-phenylethyl)adenosine, (s)-isomer | |||
8-(3-chlorostyryl)caffeine | 8-(3-chlorostyryl)caffeine : Caffeine substituted at its 8-position by an (E)-3-chlorostyryl group. 8-(3-chlorostyryl)caffeine: adenosine antagonist | monochlorobenzenes; trimethylxanthine | adenosine A2A receptor antagonist; EC 1.4.3.4 (monoamine oxidase) inhibitor |
isoalloxazine | isoalloxazine: structure | benzo[g]pteridine-2,4-dione | |
ciproxifan | aromatic ketone | ||
bw a1433 | BW A1433: adenosine receptor antagonist | ||
fk 453 | FK 453: adenosine A1 receptor antagonist; structure given in first source; a new antihypertensive agent with diuretic action in isolated rabbit aorta; FR113452 is the S-(-) enantiomer of FK 453 | ||
kf 17837 | |||
mrs 1754 | oxopurine | ||
cv 1808 | 2-phenylaminoadenosine: has coronary & cardiohemodynamic effects | purine nucleoside | |
binodenoson | |||
n(6)-cyclohexyladenosine | N(6)-cyclohexyladenosine: structure given in first source; receptors, purinergic P1 agonist | ||
st 1535 | |||
2-(2-(4-chlorophenyl)ethoxy)adenosine | 2-(2-(4-chlorophenyl)ethoxy)adenosine: a adenosine A2A receptor agonist | ||
2-(2-furanyl)-7-(2-(4-(4-(2-methoxyethoxy)phenyl)-1-piperazinyl)ethyl)-7h-pyrazolo(4,3-e)(1,2,4)triazolo(1,5-c)pyrimidine-5-amine | |||
n(6)-(2,2-diphenylethyl)adenosine | N(6)-(2,2-diphenylethyl)adenosine: adenosine receptor agonist; structure given in first source | ||
cgs 24012 | CGS 24012: adenosine agonist with both high affinity & selectivity for the adenosine A2 receptor | ||
n-cyclopropyl adenosine-5'-carboxamide | |||
sch 442416 | SCH 442416: an adenosine A2A receptor ligand | triazolopyrimidines | |
mrs 3558 | |||
cvt-6883 | 3-ethyl-1-propyl-8-(1-(3-trifluoromethylbenzyl)-1H-pyrazol-4-yl)-3,7-dihydropurine-2,6-dione: structure in first source | ||
tozadenant | tozadenant: an adenosine A2A receptor antagonist | benzothiazoles | |
psb 36 | 1-butyl-8-(3-noradamantyl)-3-(3-hydroxypropyl)xanthine: an A1 receptor antagonist | oxopurine | |
bay 60-6583 | BAY 60-6583 : A member of the class of cyanopyridines that is 6-amino-3,5-dicyano-4-(4-hydroxyphenyl)-2-sulfanylpyridine in which the hydroxy and sulfanyl hydrogens are replaced by cyclopropylmethyl and carboxamidomethyl groups respectively. BAY 60-6583: structure in first source | aminopyridine; aromatic ether; aryl sulfide; cyanopyridine; cyclopropanes; monocarboxylic acid amide | adenosine A2B receptor agonist; anti-inflammatory agent; cardioprotective agent |
atrial natriuretic factor | Atrial Natriuretic Factor: A potent natriuretic and vasodilatory peptide or mixture of different-sized low molecular weight PEPTIDES derived from a common precursor and secreted mainly by the HEART ATRIUM. All these peptides share a sequence of about 20 AMINO ACIDS. | polypeptide | |
v 2006 | 3-(4-amino-3-methylbenzyl)-7-(2-furyl)-3H-(1,2,3)triazolo(4,5-d)pyrimidine-5-amine: antiparkinson agent; structure in first source | ||
psb603 | PSB603: an adenosine A2B receptor antagonist | ||
natriuretic peptide, brain | Natriuretic Peptide, Brain: A PEPTIDE that is secreted by the BRAIN and the HEART ATRIA, stored mainly in cardiac ventricular MYOCARDIUM. It can cause NATRIURESIS; DIURESIS; VASODILATION; and inhibits secretion of RENIN and ALDOSTERONE. It improves heart function. It contains 32 AMINO ACIDS. | polypeptide | |
psb 11 | |||
n-benzo(1,3)dioxol-5-yl-2-(5-(2,6-dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1h-purin-8-yl)-1-methyl-1h-pyrazol-3-yloxy)-acetamide | |||
luf 5834 | 2-amino-4-(4-hydroxyphenyl)-6-(1H-imidazol-2-ylmethylsulfanyl)pyridine-3,5-dicarbonitrile: structure in first source |